

30 April 2024

Privatisation by way of scheme of arrangement

Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

| Party | Date | Purchase / | Number of shares | Price per share | Resultant balance | Percentage of class |
|-----------|---------------|------------|------------------|-----------------|-------------------------|---------------------|
| | | Sale | | | (including those of any | (including those of |
| | | | | | person with whom | any person with |
| | | | | | there is an agreement | whom there is an |
| | | | | | or understanding) | agreement or |
| | | | | | | understanding) |
| Zhao Hong | 29 April 2024 | Purchase | 300,000 | \$0.0000 | 13,079,690 | 2.0802% |

End

Note:

Zhao Hong is a Class (1) associate connected with the Offeree company by virtue of class (2) of the definition of acting in concert and a Class (1) associate connected with the Offeror by virtue of class (6) of the definition of acting in concert.

Dealings were made for his own account.



On 29 April 2024, 300,000 share awards were vested on Zhao Hong pursuant to the Post-IPO RSU Plan adopted by the Company.

The resultant balance of 13,079,690 shares held include 11,979,690 shares held by Convergence International Holdings Ltd. and 1,100,000 shares held by Zhao Hong.